What is Floreo?
Headquartered in Washington, D.C., Floreo, Inc. operates at the intersection of health-tech and education. The company provides a specialized virtual reality platform designed to teach essential social, communication, and life skills to individuals with ASD. By utilizing a patented process that pairs VR headsets with interactive, real-world simulations, Floreo offers a supervised environment for cognitive development. This approach addresses a significant gap in traditional therapy, providing a scalable, repeatable, and engaging method for skill acquisition that can be deployed in clinical, educational, or home settings. As the demand for accessible, outcomes-based neurodevelopmental support grows, Floreo's platform serves as a vital tool for clinicians and caregivers alike.
How much funding has Floreo raised?
Floreo has raised a total of $10.3M across 3 funding rounds:
Debt
$150K
Debt
$156K
Series A
$10M
Debt (2020): $150K with participation from PPP
Debt (2021): $156K led by PPP
Series A (2022): $10M supported by Tenfore Holdings, Felton Group, The Autism Impact Fund, and The Disability Opportunity Fund
Key Investors in Floreo
Tenfore Holdings
A New York-based global investment firm specializing in growth-stage and middle-market investments across sectors including personalized medicine and AI-powered analytics.
The Autism Impact Fund
A healthcare technology and innovation firm dedicated to investing in behavioral health, mental health, and solutions for neurodevelopmental disorders.
The Disability Opportunity Fund
A nationally certified CDFI providing financial products and advisory services to improve the quality of life and economic outcomes for people with disabilities.
What's next for Floreo?
With the recent influx of capital, Floreo is well-positioned to scale its operations and deepen its research partnerships. The strategic focus will likely center on expanding the library of VR-based scenarios, enhancing the platform's data analytics capabilities to track patient progress more effectively, and broadening its reach into institutional healthcare networks. By aligning with investors who specialize in behavioral health and disability-focused innovation, the company is poised to solidify its market leadership. Future growth will likely involve navigating the complexities of digital health reimbursement models and expanding the accessibility of its technology to underserved populations, ensuring that its evidence-based interventions become a standard component of modern neurodevelopmental care.
See full Floreo company page
